 |
[Alpha Biz=(Chicago) Reporter Paul Lee] Samsung BioLogics' annual consignment production (CMO) orders exceeded KRW 3 trillion for the first time.
Samsung BioLogics said on the 28th that it has signed one new contract with an Asian-based pharmaceutical company and four CMO contracts.
The total amount of orders received through new contracts and increased contracts amounted to 760.8 billion won, up to 588.8 billion won and 171.9 billion won, respectively. Samsung Bio did not disclose the company name and product name at the request of the contracting company.
As a result, Samsung Biologics' cumulative annual order amounted to 3.4867 trillion won, exceeding 3 trillion won for the first time. This year's cumulative order amount is twice as much as last year's order amount of 1.7835 trillion won.
Samsung BioLogics said it is strengthening partnerships with global pharmaceutical companies by expanding contracted products after the first contract or expanding the production size of the previously contracted volume. He also added that there are nine large-scale contracts worth more than 100 billion won among new orders and increase contracts announced this year. As a result, Samsung Bio raised its sales forecast for this year to 3.6016 trillion won from 3.5265 trillion won last month.
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
